Sign Up | Log In | What is SocialPicks?

American Oriental Bioengineering Inc (AOB) Trade Now » Rate AOB - Discuss AOB - Add to Watch List

Sector: Healthcare > Industry: Biotechnology & Drugs

SocialPicks Sentiment:

** v.s. other stocks

This Quarter's Sentiment:

All:

91.0%

Top:

100.0%

Rate AOB:

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

ROCK-STAR INVESTORS

Rank	Name	Sharpe Ratio	Avg Return	Followers
1	noshoes	21.10	+34.44%	381
2	Gerald Greene	18.14	+68.27%	211
3	stockmarketfunding.com	17.66	+25.61%	55
4	akiralegrand	13.47	+14.32%	62
5	anup2104	12.13	+74.42%	40

... more »

POPULAR STOCKS

Symbol	Company Name	Sentiment
AMZN	Amazoncom Inc
RIO	Companhia Vale Do Rio Doce
GLD	streetTRACKS Gold
AAPL	Apple Computer Inc
WMT	WalMart Stores Inc
SBUX	Starbucks Corp

... more »

TODAY'S HEADLINES

LDK Solar's Growth Potential Offset by Gross Margin Pressure
by Paul Cheung (Zacks.com) about LDK

Cisco Systems Still a Wait and See
by Thomas Catino (Ant & Sons) about CSCO

The Merrill Lynch Diet: Starving Shareholders
by Zack Miller (BloggingStocks) about MER

Until Housing Improves, Don't Expect Stocks to Rebound
by J.D. Steinhilber (Agile Investing) about SPY

Google Blows Q2: Multiple Compression to Continue
by Henry Blodget about GOOG

... more »

TODAY'S TOP PICKS

DNDN		Cancer Vaccines: Investing Opportunities beyond Dendreon (NASDAQ: D... by Mike Havrilla
CLDA		BioMed Research Reports: Clinical Data (NASDAQ: CLDA), Lpath (OTC: ... by Mike Havrilla
PARD		Biotech Stocks - Beware of The Covered Call Trap by Ivan Mutaftchiev
PBIO		Under the Radar Healthcare Stocks: Protox, Pressure BioSciences, Un... by Mike Havrilla
ISIS		ISIS - Last Tuesday's Drop Presents a Nice Buy Opportunity by Ivan Mutaftchiev

... more »

StreetInsider.com on AOB

Visit streetinsider.com

Discussion Wall

+ Add

amritadas (+0.00%)

Upcoming FDA decision on the approval of a new Gout.. - An upcoming treatment by a small cap company for Gout to face FDA decision on approval shortly. Gout has traditionally been a difficult disease to tre

+	0 replies

amritadas (+0.00%)

A FREE report on the approval of a new Gout Drug - An upcoming treatment by a small cap company for Gout to face FDA decision on approval shortly. Gout has traditionally been a difficult disease to tre

+	0 replies

amritadas (+0.00%)

A FREE report on the approval of a new Gout Drug - FDA Panel to review this Biotech company's stress agent drug on July 28th. If they get a favorable backing by the panel, the chances of approval by th...

+	0 replies

newsmonkey (-19.36% risk: conservative)

For detailed analysis and early notification of my .. - Fill in the form found here and you will receive detailed analysis and details of my selection criteria. https://spreadsheets.google.com/a/newsdropp

+	1 reply

... more »

More Resources

About American Oriental Bioengineering Inc - Answers.com

Historical Prices - Yahoo

Message Boards - BoardCentral.com

More Info: Yahoo | Google | Reuters

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.